ArticleNPJ precision oncology2026
Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC) is associated with significant toxicity and limited pathological responses. We retrospectively compared a radiotherapy‑free regimen of camrelizumab plus modified FOLFOXIRI versus modified FOLFOXIRI alone in consecutive patients with clinical stage II-III LARC treated from 2022-2025 (n = 146). All patients received ≥3 cycles of neoadjuvant therapy; surgery or watch‑and‑wait was determined by a multidisciplinary team. Baseline characteristics were well balanced. Among surgical patients, pCR rates were 29.8% with camrelizumab plus FOLFOXIRI and 19.6% with FOLFOXIRI alone. Radiologic objective response rates were 70.7% and 53.5%, respectively, and mean neoadjuvant rectal scores were lower with camrelizumab (13.95 vs 23.77; P < 0.02). Disease‑free survival was significantly improved in the camrelizumab group, while overall survival was similar at current follow‑up. Grade 3-4 hematologic and gastrointestinal toxicities were comparable, and no unexpected immune‑related events occurred. Camrelizumab plus FOLFOXIRI appears to be an active, tolerable radiotherapy‑free neoadjuvant option for LARC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.